Evidence map›Paper›PMID 27920500›Full record

ArticleDrug design, development and therapy2016

Design, synthesis and evaluation of VEGF-siRNA/CRS as a novel vector for gene delivery.

Wen Zhao, Yifan Zhang, Xueyun Jiang, Chunying Cui

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Wen ZhaoSchool of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing, China.
Yifan ZhangSchool of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing, China.
Xueyun JiangSchool of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing, China.
Chunying CuiSchool of Chemical Biology and Pharmaceutical Sciences, Capital Medical University, Beijing, China.
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small interfering RNA (siRNA) delivery is a prospective method in gene therapy, but it has application limitations such as negative charge, water solubility and high molecular weight. In this study, a safe and efficient nano-vector, CRS, was designed and synthesized to facilitate siRNA delivery. Physical and chemical properties of VEGF-siRNA/CRS were characterized by methods including scanning electron microscopy (SEM), transmission electron microscopy, zeta potential (

Indexed as

Genetic TherapyRNA InterferenceAnimalsAntineoplastic AgentsCell SurvivalDown-RegulationDrug Delivery SystemsDrug LiberationHeLa CellsHumansMaleMiceMice, Inbred ICRNanoparticlesNeoplasmsOligopeptidesAntineoplastic Agentsarginyl-glycyl-aspartyl-serineOligopeptidesRNA, Small InterferingVascular Endothelial Growth Factor Aantitumorbiophysical characteristicsCRSgene silencingprotein expressionsiRNA deliverytumor therapyVEGF

Identifiers

PMID27920500
PMCPMC5125806
OpenAlexW2553093780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.